john-orloff

Baxter takes R&D head from Merck Serono

pharmafile | July 15, 2014 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck Serono, baxter, john orloff 

Baxter International has appointed Dr John Orloff as its vice president and global head of R&D development for Baxter BioScience.

Orloff joins the US firm from Merck Serono where he served as global head of clinical development. Orloff will be responsible for advancing the late-stage BioScience pipeline and R&D operating model at the company which is splitting into two entities.

Prior to his tenure at Merck Serono Orloff spent around 10 years at Novartis, where he served as chief medical officer for global development. Earlier in his career, Orloff supported clinical development at Merck Research Labs and was previously a faculty member at the Yale University School of Medicine.

Advertisement

Ludwig Hantson who is the president of Baxter BioScience, says: “John brings significant scientific and leadership expertise, including pre-clinical research, clinical development, and medical and regulatory affairs. He will be a valuable member of our executive leadership team and a guiding force for effectively executing the development strategy for our organisation.”

Related Content

Baxter expands US portfolio with new injectables

Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of …

baxter

Baxter partners up with Mayo Clinic for new “centre of exellence” in renal care

American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a …

baxter

Baxter hikes 2016 earnings view driven by strong Q1 results

Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. …

The Gateway to Local Adoption Series

Latest content